Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International Breast Cancer Intervention Study

Next Previous
X
Search
Trial Profile

International Breast Cancer Intervention Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anastrozole (Primary)
  • Indications Breast cancer; Ductal carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms IBIS-II; IBIS-II Bone; IBIS-II-Prevention

    • Most Recent Events

    • 05 Dec 2023 Results assessing the effects of serum oestradiol and testosterone concentrations on the efficacy of the aromatase inhibitor anastrozole for the prevention of breast cancer in postmenopausal women at high risk, published in the Lancet Oncology.
    • 05 Oct 2021 Status changed from active, no longer recruiting to completed.
    • 22 Jan 2021 Results of the BMD substudy assessing Off-treatment bone mineral density changes in postmenopausal women published in the British Journal of Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top